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A B S T R A C T
Breath analysis offers a non-invasive and rapid diagnostic method for detecting various volatile organic com-
pounds that could be indicators for different diseases, particularly metabolic disorders including type 2 diabetes
mellitus. The development of type 2 diabetes mellitus is closely linked to metabolic dysfunction of adipose tissue
and adipocytes. However, the VOC profile of human adipocytes has not yet been investigated. Gas chromato-
graphy with mass spectrometric detection and head-space needle trap extraction (two-bed Carbopack X/
Carboxen 1000 needle traps) were applied to profile VOCs produced and metabolised by human Simpson Golabi
Behmel Syndrome adipocytes. In total, sixteen compounds were identified to be related to the metabolism of the
cells. Four sulphur compounds (carbon disulphide, dimethyl sulphide, ethyl methyl sulphide and dimethyl
disulphide), three heterocyclic compounds (2-ethylfuran, 2-methyl-5-(methyl-thio)-furan, and 2-pentylfuran),
two ketones (acetone and 2-pentanone), two hydrocarbons (isoprene and n-heptane) and one ester (ethyl
acetate) were produced, and four aldehydes (2-methyl-propanal, butanal, pentanal and hexanal) were found to
be consumed by the cells of interest. This study presents the first profile of VOCs formed by human adipocytes,
which may reflect the activity of the adipose tissue enzymes and provide evidence of their active role in me-
tabolic regulation. Our data also suggest that a previously reported increase of isoprene and sulphur compounds
in diabetic patients may be explained by their production by adipocytes. Moreover, the unique features of this
profile, including a high emission of dimethyl sulphide and the production of furan-containing VOCs, increase
our knowledge about metabolism in adipose tissue and provide diagnostic potential for future applications.
1. Introduction
Volatile organic compounds (VOCs) being produced by a human
organism mirror normal and abnormal physiological processes and
have, therefore, a great potential for use in medical diagnosis and
therapy monitoring [1,2]. These compounds make up the human vo-
latilome [3] and stem from various sources. While some of these VOCs
are of endogenous origin, others can derive from exogenous sources
such as diet, environmental exposure, or microbiota activity. It has been
demonstrated that abnormal processes, such as metabolic disorders,
cancer, or other diseases can influence the volatilome profile by pro-
ducing new VOCs, or by altering the concentrations of the VOCs that
are produced normally by the human organism. The detection of these
changes, via analysis of VOCs emitted by breath, skin, and other bodily
fluids such as urine, saliva, or sweat, provides a unique opportunity to
track microbiota activity, exposure to environmental toxins, or screen/
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monitor various diseases including cancer [1,4–6]. Despite this huge
potential, the use of the human volatilome within a clinical setting is
limited. A major unresolved issue is the poor understanding of the
origin, behaviour, and metabolic fate of VOCs in human body.
VOC in vitro studies, involving cell cultures or pathogenic micro-
organisms (bacteria, fungi), could partially address this issue. In par-
ticular, this approach is of considerable importance for the exploration
and understanding of blood-borne compounds observed in exhaled
breath and other body emanations. For example, during the last few
years a substantial effort has been made to identify volatiles released or
consumed by cancer cells [7–10], bacteria [11–14], and fungi [15].
White adipose tissue is a major endocrine organ and secretes various
bioactive compounds which are involved in different physiological and
metabolic processes [16]. If production and release are dysregulated, as
it is in the case of obesity, these compounds contribute to the devel-
opment of metabolic disorders including diabetes, kidney and cardio-
vascular diseases, and thus can be used for diagnostic purposes [17].
Some recent studies were able to detect VOC changes in patient with
chronic kidney disease and diabetes [18–21]. Diabetes, kidney disease,
and cardiovascular disease are known to be interrelated and they are
linked with obesity [17,22–25]. Thus, the mechanism that underlies
their development takes place in adipocytes and the adipose tissue
[17,26–29]. However, the VOC profile of human adipocytes has not
been investigated yet.
Here, we report details on the VOCs produced and metabolised by
human Simpson-Golabi-Behmel syndrome (SGBS) adipocytes, which
are well-established model cells for investigating metabolism in human
fat tissue [30]. For this purpose, gas chromatography with mass spec-
trometric detection (GC–MS) and head-space needle trap extraction
(two-bed Carbopack X/Carboxen 1000 NT needle traps) as the pre-
concentration method have been applied.
2. Materials and methods
2.1. Chemicals and calibration mixtures
Multi-compound calibration mixtures were prepared from high-
purity liquid substances. The reference substances with purities ranging
from 95 to 99.9% were purchased from Sigma-Aldrich (Austria) and
Fluka (Switzerland). A detailed description of the production of gaseous
calibration mixtures is provided elsewhere [31,32] and, therefore, only
a short outline of the procedure is provided here. Gaseous mixtures of
water soluble species were produced by means of a GasLab calibration
mixtures generator (Breitfuss Messtechnik, Germany). The device gen-
erates gas mixtures at different humidity levels via evaporation of liquid
species. To achieve desired concentrations, pure substances were ad-
ditionally diluted with water at the ratios of 1:2000–1:3000. Effec-
tively, gas mixtures exhibiting VOCs volume fractions ranging from
10 ppt (parts-per-trillion) to 500 ppb (parts-per-billion) were used for
calibration. For more volatile compounds, multi-compound gaseous
standards were prepared by injecting and evaporating a few microliters
of liquid or gaseous analyte into evacuated glass bulbs (Supelco, Ca-
nada). The desired calibration levels were achieved by transferring
adequate volumes of the primary standard into Tedlar bags (SKC Inc.,
USA) filled with predefined amounts of humidified zero air, the latter
being produced by the GasLab generator. Calibration curves were ob-
tained on the basis of 2-fold analyses of five distinct and independent
concentration levels.
2.2. Adipose cells cultivation
Human Simpson Golabi Behmel Syndrome (SGBS) preadipocyte
cells [30] were maintained in 15mL DMEM/Ham's F12 (1:1) medium
(Invitrogen, Paisley, UK) containing 10% fetal calf serum (FCS; In-
vitrogen), 100 U/mL penicillin (Invitrogen), 100 μg/mL streptomycin
(Invitrogen), 33 μM biotin, and 17 μM pantothenate. When SGBS
preadipocyte cells were near confluent, differentiation into mature
adipocytes was started. They were washed with phosphate buffered
saline (PBS) and cultured in FCS-free differentiation medium containing
DMEM/Ham's F12 (1:1) medium supplemented with 100 U/mL peni-
cillin, 100 μg/mL streptomycin, 33 μM biotin, 17 μM pantothenate,
10 μg/mL human transferrin, 10 nM insulin, 100 nM hydrocortisone,
0.2 nM triiodothyronine, 25 nM dexamethasone, 500 μM 3-isobutyl-1-
methylxanthine (IBMX), and 2 μM rosiglitazone. After four days, this
medium was replaced by differentiation medium excluding dex-
amethasone, IBMX, and rosiglitazone and cells were cultured for up to
10 days.
The glass cultivation and measurement flasks (Ruprechter, Austria)
occupy a volume of 21× 5.5× 11.5 cm3 (1 L nominal volume, bottom
area of approximately 240 cm2). Their detailed description is given
elsewhere [7]. In total 12 pairs of samples (cell culture and medium
without cells) were prepared.
2.3. Sample preparation and head-space needle trap extraction procedure
Volatiles released by cells were pre-concentrated using head-space
needle trap extraction. Two-bed 23-gauge Silcosteel-treated stainless
steel needle trap devices (NTD) (2 cm of Carbopack X and 1 cm of
Carboxen 1000, both 60/80 mesh, PAS Technology, Germany) were
employed for trapping the VOCs. Prior to their use all NTDs were pre-
conditioned at 290 °C by flushing them with high-purity nitrogen
(6.0–99.9999%) for 15min. The NTD trapping of the head space con-
stituents was performed dynamically by inserting the NTD via a septum
into a cultivation flask and drawing 100mL of the head space gas at a
steady flow rate of 2mL/min. To maintain a constant pressure in the
flask during sampling high purity zero air was continuously introduced
into the flask at a flow equal to the sampling flow. Following extraction,
the NTD was introduced into the inlet of the gas chromatograph where
the volatiles were thermally desorbed at 290 °C in a splitless mode
(1min). In parallel, one blank sample containing nitrogen was analyzed
using the same protocol to identify possible contaminants stemming
from sources other than cells/medium. The resulting concentration le-
vels were subtracted (if applicable) from the respective values in the
associated HS samples.
2.4. Chromatographic analysis
Chromatographic analyses were carried out using an Agilent
7890A/5975C GC–MS instrument (Agilent, USA). During desorption
the GC inlet operated in the splitless mode (1min), followed by a split
mode using a ratio of 1 to 50. VOCs were separated using an Rt-Q-
BOND column (30m×0.25mm, film thickness 8 μm, 100% divi-
nylbenzene phase, Restek, USA) working in a constant flow of helium at
1mL/min. The column temperature program was as follows: 40 °C for
1min, increased at a rate of 5 °Cmin−1 to 210 °C, a constant tem-
perature of 210 °C for 4min, increased at a rate of 3 °C×min−1 to
260 °C, and a constant temperature of 260 °C for 14min. The mass
spectrometer worked in a combined SCAN/SIM mode. The SCAN mode
with m/z ranging from 20 to 200 was used for the identification of
compounds as well as for the quantification of more abundant species.
In case of the latter, peak integration was based on extracted ion
chromatograms. The substance specific m/z ratios allowed in majority
of cases for a separation of the peaks of interest from its neighbors, even
when the latter were overlapping in the total ion count chromatogram.
Selected less abundant VOCs were quantified using SIM (selective ion
monitoring mode). The applied SCAN quantifier ions and SIM m/z va-
lues, and dwell times are given in Table 1. The quadrupole, ion source
and transfer line temperatures were kept at 150 °C, 230 °C and 280 °C,
respectively.
The identification of compounds was performed in two steps.
Firstly, the peak spectrum was checked against the NIST mass spectral
library. Next, the NIST identification was confirmed by comparing the
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respective retention times with retention times obtained for reference
mixtures prepared as outlined above.
3. Results and discussion
3.1. Method validation
The validation parameters for VOCs under study are given in
Table 1. Limits of detection (LOD) were estimated using the procedure
proposed by Huber [33]. More specifically, the standard deviation of 5
consecutive blank signals and 1% probability (1-α) for the type 1 error
resulting in the coverage factor of 4.1 were used for these purposes. The
LODs ranged from 0.03 to 5 ppb. The limit of quantification (LOQ) was
defined as 3.3× LOD. Relative standard deviations (RSDs), calculated
on the basis of the consecutive analyses of 5 medium samples, varied
from 5 to 12% and were considered appropriate for the purpose of this
study. The GC–MS instrument response was found to be linear within
the investigated concentration ranges (Table 1), with coefficients of
determination ranging from 0.969 to 0.999.
3.2. Adipose cell cultures
The total number of adipose cells in particular experiments and
their viability at the time of measurement are shown in Table 2. The
total number of cells fell within the range of 1.25×106 and 4.12×106
(mean 2.6×106), whereas the viability varied from 85.4% to 97.1%
(mean 92.4%). Consequently, the applied experimental procedure did
not affect the cells' viability and it can be assumed that the release and
uptake of the head-space VOCs mirror their metabolism.
3.3. Volatiles released and metabolised by adipose cells
A Wilcoxon signed rank test was used to evaluate the production
and consumption of VOCs by the cells under study, and p < 0.05 was
taken as being significant. For the purpose of the Wilcoxon test the left-
censored data were estimated by a value LOQ/√2, or LOD/√2 [34].
Levels of 16 compounds were found to be significantly dependent on
the presence of the adipose cells in the cultivation flask. Their detection
and quantification incidences, as well as their concentrations in the
cultures head-space (ppb), are given in Table 3. Twelve VOCs were
produced and a further four were metabolised by the adipose cells
under study. Amongst the liberated compounds there were four volatile
sulphur compounds (carbon disulphide (CS2), dimethyl sulphide
(DMS), ethyl methyl sulphide (EMS) and dimethyl disulphide (DMDS)),
three heterocyclic compounds (2-ethylfuran, 2-methyl-5-(methyl-thio)-
furan and 2-pentylfuran), two ketones (acetone and 2-pentanone), two
hydrocarbons (isoprene and n-heptane) and one ester (ethyl acetate).
All metabolised species belong to aldehydes. All compounds but one,
(2-methyl-5-(methylthio)-furan), were quantified using the aforemen-
tioned procedures. 2-methyl-5-(methylthio)-furan was not quantified
due to problems related to the preparation of reliable reference mix-
tures and its levels were assessed only on the basis of peak areas. The
highest concentration levels were noted for DMS (median of 317 ppb in
the cell cultures) and acetone (57 ppb). The majority of the remaining
species exhibited median concentration values below 5 ppb.
A total of four aldehydes (2-methyl-propanal, butanal, pentanal,
and hexanal) were metabolised by SGBS adipocytes. This finding agrees
with results from other human cell cultures, in which consumption of
aldehydes is commonly observed [7–10,35,36] and ascribed to the ex-
pression of aldehyde dehydrogenases (ALDHs) irreversibly oxidizing
compounds from this chemical family into their corresponding car-
boxylic acids [37,38]. Indeed, fatty aldehyde dehydrogenase (FALDH)
has been identified in rat adipocytes as a key component of the de-
toxification pathway of aldehydes arising from lipid peroxidation
events [39,40]. Alternatively, aldehydes could also be reduced to al-
cohols by alcohol dehydrogenases (ADHs). However, low levels of
ADHs in adipocytes render the oxidation of aldehydes by ALDHs a more
plausible reason for aldehydes uptake [40].
A number of metabolic pathways could be involved in the produc-
tion of acetone and 2-pentanone by cells under scrutiny. These
Table 1
Retention times (Rt) [min], quantifier ions, SIM dwell times [μs], LODs [ppb], RSDs (%), coefficients of variation (R2) and linear ranges [ppb] for VOC compounds of
interest. The compound in italics was not quantified for reasons mentioned in the text. Compounds are ordered with respect to increasing retention time.
VOC CAS Rt [min] Quantifier ion (SIM dwell time [μs]) LOD RSD [%] R2 Linear range
[ppb] [pmol L−1] [ppb] [pmol L−1]
Acetone 67-64-1 19.42 43 1.0 40 6 0.979 3.3–100 129–3900
Carbon disulphide (CS2) 75-15-0 19.72 76 (80) 0.13 5.1 7 0.969 0.43–8 17–310
Dimethyl sulphide (DMS) 75-18-3 19.97 62 4.0 156 10 0.998 13–500 510–19,500
Isoprene 78-79-5 22.21 67 (80) 0.16 6.3 7 0.970 0.53–5 21–200
Propanal, 2-methyl 78-84-2 24.09 72 5 200 7 0.993 16.5–180 640–7000
Butanal 123-72-8 25.36 72 5 200 12 0.996 16.5–40 640–1600
Ethyl methyl sulphide (EMS) 624-89-5 26.09 61 (80) 0.04 1.6 9 0.998 0.13–4.5 5.2–180
Ethyl acetate 141-78-6 26.44 43 0.7 27 8 0.998 2.3–17 90–660
2-Ethylfuran 3208-16-0 30.58 81 (80) 0.03 1.2 11 0.999 0.1–4 3.9–160
2-Pentanone 107-87-9 30.76 43 0.06 2.4 10 0.999 0.2–10 7.7–390
Pentanal 110-62-3 31.05 58 1.8 70 9 0.999 6.0–38 230–1500
Dimethyl disulphide (DMDS) 624-92-0 31.78 94 0.05 2.0 8 0.987 0.17–4.3 6.4–170
n-Heptane 142-82-5 33.31 71 (80) 0.03 1.2 5 0.974 0.1–2.5 3.9–98
Hexanal 66-25-1 36.03 56 1.2 47 7 0.999 3.9–250 150–9800
2-Methyl-5-(methyl thio) furan 2371-70-2 42.80 128 (80) – – – – – –
2-Pentylfuran 3777-69-3 48.00 81 (80) 0.03 1.2 12 0.998 0.1–5 3.9–200
Table 2
Total number of cells, number of living cells and viability at the time of the
measurement.
Culture Total number of cells
×106




1 1.28 1.15 90.2
2 2.63 2.55 97.1
3 2.07 1.88 90.4
4 2.45 2.38 96.9
5 2.90 2.78 95.7
6 1.85 1.75 94.6
7 2.56 2.28 89.1
8 2.32 2.20 94.8
9 3.04 2.60 85.5
10 2.84 2.72 95.8
11 3.12 2.92 93.6
12 4.12 3.52 85.4
Mean 2.60 2.39 92.4
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embrace: (i) ADHs-related oxidation of secondary alcohols, (ii) β-oxi-
dation of branched-chain fatty acids, and (iii) decarboxylation of
Acetyl–CoA. Although ADHs are mainly responsible for ethanol meta-
bolism; they are also capable of oxidizing long-chain, cyclic and sec-
ondary alcohols [37,41]. Thus, 2-pentanone may be the product of 2-
pentanol oxidation; whereas, acetone can derive from 2-propanol. Even
though 2-pentanol was not detected in the cultures/media head-space,
huge amounts of 2-propanol were present in the applied medium. In-
terestingly, 2-pentanone liberation has been previously seen for hepa-
tocyte carcinoma cells (HepG2), lung adenocarcinoma cells (A549),
human bronchial epithelial primary cells (HBEpC) and human fibro-
blasts (hFB) [7,8]. β-Oxidation of fatty acids is another potential source
of ketones in humans. For example, 2-heptanone and 4-heptanone are
the products of the 2-ethylhexanoic acid oxidation [42], and 2-propyl
pentanoic acid is metabolised to 3-heptanone [43]. Walker et al. [44]
provided some evidence that 2-pentanone could be produced in an
analogous way in the peroxisomal pathway through β-oxidation of
hexanoic acid. Acetone is a major volatile in the human body found in
breath, blood, and urine [32,45–47]. It is mainly formed in the liver
during fatty acids oxidation from acetoacetate undergoing spontaneous
decarboxylation [47,48].
CS2, DMS, EMS and DMDS, were produced by adipocytes, with DMS
having the highest concentration of all liberated compounds. The pre-
sence of some volatile sulphur compounds in human organism is being
linked to the metabolism of two sulphur-containing amino acids; me-
thionine and cysteine. DMS was suggested to be produced by thiol S-
methyltransferase via the methylation of methanethiol [49]. The latter
in turn can be formed from (i) methionine by L-methionine γ-lyase, or
(ii) hydrogen sulphide (H2S) by S-methyltransferase. In the latter case
H2S can stem from desulphhydration of cysteine performed by cy-
stathionine-β-synthase (CBS), cystathionine γ-lyase (CSE) and 3-mer-
captopyruvate sulphurtransferase [49]. Analogously, S-methyl-
transferase could form other methyl thioethers, such as e.g. EMS, via
the methylation of respective thiols. Recently, a small population study
with diabetic and non-diabetic human subjects found differences in the
concentrations of sulphur compounds in breath, with higher con-
centrations of methanethiol being found in diabetic patients and a trend
for higher DMS with increasing H2S [21]. We therefore suggest that the
increased production of sulphur compounds in diabetic patients might
stem from adipocytes in adipose tissue. CS2 is presumably an environ-
mental or occupational intoxicant absorbed by inhalation, oral, and
dermal routes [50]. In humans it is metabolised to carbonyl sulphide,
atomic sulphur and monothiocarbonate by cytochrome P450 mono-
oxygenase [50]. Although at present the metabolic pathways leading to
the CS2 production are unknown, it has been recently suggested to play
a bioregulatory or therapeutic roles in mammals [50].
Isoprene is a terpenoid of unclear origin and function in the human
organism. In mammals it is postulated to be produced from isopentenyl
pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate
(DMAPP) in the mevalonic acid (MVA) pathway [51]. More specifically,
it is suggested to be produced in the cytosol of hepatocytes during acid-
catalyzed formation from DMAPP [52]. However, this reaction is too
slow to explain high isoprene levels in human organism [53]. More-
over, a number of recent studies suggest that other metabolic pathways
may contribute to isoprene production in humans [35,54,55]. Inter-
estingly, in breath gas analysis this species is considered to be of use as
a sensitive non-invasive biomarker for several metabolic effects in hu-
mans [51,56,57]. It is also postulated to offer some protection against
oxidative stress, analogously to that hypothesized in plant physiology,
and act as a reactive oxygen species sweeper reacting with radicals
through the double bond system [55,58]. More recently, Neupane et al
[18] have found that isoprene rises during hypoglycaemia in diabetic
subjects. However, the mechanism behind this increase of isoprene is
unclear. Thus, again, our data are indicating that this rise of isoprene is,
at least in part, based on its production in adipocytes. The metabolic
pathways leading to the formation of n-heptane by the adipocytes under
scrutiny remain unclear. It could be assumed that it is produced during
lipid peroxidation processes, but this needs to be addressed in future
studies. It should also be mentioned here that n-heptane was found to
be consumed by lung cancer cells (A549) [59].
Ethyl acetate seems to derive from the esterification of ethanol with
acetic acid. Although, this reaction in the absence of a catalyst is ex-
pected to be very slow, ethyl acetate could be formed from acetic acid,
which is a common volatile found in the human organism originating
from normal human biochemistry (e.g. Krebs cycle, pyruvate metabo-
lism, or ethanol metabolism). Indeed, ethanol was observed to be pre-
sent the cell culture and media head-space. The production of ethyl
acetate, similar as in the case of SGBS adipocytes, has been reported in
cultures of human umbilical vein endothelial cells (HUVEC) and lung
adenocarcinoma cells (A549) [36,59].
Three heterocyclic compounds belonging to the furan family (2-
ethylfuran, 2-methyl-5-(methyl-thio)-furan and 2-pentylfuran) were
Table 3
Detection (nd) and quantification (nq) incidences, concentration ranges, and medians of VOCs under study in the headspace of media and cell cultures. The compound
in italics was not quantified for reasons mentioned in the text (the peak area is provided). Compounds are ordered with respect to increasing retention time.









[ppb] [pmol L−1] [ppb] [pmol L−1]
Uptake Propanal, 2-methyl 78-84-2 12(12) 21–56 (30) 820–2200 (1200) 12(12) 51–235 (83) 2000–9200 (3200) 4.88× 10−4
Butanal 123-72-8 6(1) 20 780 12(8) 19–36 (29) 740–1400 (1100) 4.88× 10−4
Pentanal 110-62-3 12(3) 6.7–7.7 (7.4) 260–300 (290) 12(12) 7.2–49 (8.6) 280–1900 (340) 4.88× 10−4
Hexanal 66-25-1 12(10) 3.6–8.5 (6.5) 140–330 (250) 12(12) 7.5–424 (14) 290–16,500 (550) 1.47× 10−3
Release Acetone 67-64-1 12(12) 25–94 (57) 980–3700 (2200) 12(12) 6.9–8.0 (7.6) 270–310 (300) 4.88× 10−4
Carbon disulphide 75-15-0 12(12) 2.1–8.0 (2.5) 80–310 (100) 12(12) 0.7–1.6 (1.1) 27–62 (43) 4.88× 10−4
Dimethyl sulphide 75-18-3 12(12) 171–480 (317) 6700–18,700 (12,300) 9(0) < LOQ <LOQ 4.88× 10−4
Isoprene 78-79-5 12(9) 0.5–2.9 (1.3) 20–110 (50) 12(7) 0.5–1.1 (0.9) 20–43 (35) 1.17× 10−3
Ethyl methyl sulphide 624-89-5 12(6) 0.15–1.14 (0.34) 6–44 (13) 0(0) < LOD <LOD 4.88× 10−4
Ethyl acetate 141-78-6 12(12) 4.5–11.4 (7.4) 180–440 (290) 12(10) 2.2–4.0 (3.2) 86–160 (130) 4.88× 10−4
2-Ethyl furan 3208-16-0 10(6) 0.24–1.0 (0.58) 9–39 (23) 10(0) < LOQ <LOQ 3.9× 10−2
2-Pentanone 107-87-9 12(12) 0.48–1.35 (0.72) 19–53 (28) 12(7) 0.21–0.27 (0.22) 8.2–11 (9) 4.88× 10−4
Dimethyl disulphide 624-92-0 12(12) 0.24–1.7 (0.46) 9–66 (18) 12(6) 0.25–0.37 (0.3) 9.8–14 (12) 4.88× 10−4





– 12(12) 700–1400 (1000) – 4.88×10−4
2-Pentylfuran 3777-69-3 12(10) 0.08–1.4 (0.25) 3.2–55 (10) 12(10) 0.09–0.1 (0.1) 3.5–3.9 (4) 5.0× 10−2
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also found to be released by the SGBS adipocytes. These species are not
known to be produced by human metabolism. However, the latter was
found in the breath of patients with Aspergillus fumigatus infections
[60,61] and human skin emanation [62]. They are also present in many
foods and beverages and used as flavoring agents. To the best of our
knowledge, the production of VOCs from the furan family by human
cells in vitro has not been reported before [10]. Therefore, this feature
seems to be unique for the adipocyte tissue metabolism. Interestingly,
furan has been found to be released from the prostate and has been
suggested to be of use as a biomarker for prostate cancer – even though
its origin has remained unclear [63]. Its production by natural dehy-
dration of monosaccharides and the oxidation of some fatty acids cat-
alyzed by lipoxygenases [63] could take place in adipocytes in the
context of lipid peroxidation. Whether these compounds might have a
value for use as biomarkers for metabolic diseases, including diabetes,
remains to be clarified.
3.4. Potential of adipocyte-specific volatiles as metabolic biomarkers
Type 2 diabetes mellitus is an inflammatory disease and the me-
chanism that underlies its development take place in the adipose tissue.
It is also the leading cause of kidney failure and it increases the risk of
heart attacks and strokes by the factor of 2–3 [64]. Obesity is the main
cause for type 2 diabetes mellitus and cardiovascular disease. It is also
linked to kidney disease [65–69]. Accumulating evidence indicates that
obesity causes chronic low-grade inflammation and that this con-
tributes to systemic metabolic dysfunction that is associated with obe-
sity-linked disorders [17]. Thus, the early and easy detection of a me-
tabolic switch or a dysregulated metabolism in adipose tissue via VOC
profiling could speed-up and enhance sensitivity of clinical diagnosis.
Similar to the link between diabetes, obesity, and adipose tissue
metabolism, a change in breath VOCs in diabetic patients [21] might
mirror a change in release of VOCs by adipocytes. It has been hy-
pothesized previously that a metabolic switch, which enables adipo-
cytes to survive and sustain stress episodes, e.g. hypoxia (as it is the
case in the obese state) may provide energy abundance and trigger li-
pogenesis [70]. In the long term, this could explain the vicious circle of
exacerbating obesity, shifted metabolism and metabolic disease mani-
festation. In agreement with this, comprehensive microarray analysis
has found striking correlations between the gene expression pattern of
human adipocytes and matched biomarkers for metabolic diseases in-
cluding diabetes and insulin resistance [70].
4. Conclusions
The present study is the first study to provide a VOC profile of
human adipocytes. It underlines the potential of VOC analysis as a
potential non-invasive tool for monitoring metabolic changes in adipose
tissue as well as the whole body. Sixteen VOCs were found to be related
to the metabolism of the cells under study. Twelve VOCs were found to
be produced and a further four metabolised. There are two unique
features of the VOC fingerprint formed by the SGBS adipocytes: (i) the
presence of VOCs from the furan family and (ii) a very high production
of dimethyl sulphide. Although the exact pathway of the DMS pro-
duction remains unclear, the presence of this species might mirror the
activity of enzymes detoxifying reactive volatile sulphur compounds
converting them into less toxic forms. Moreover, the release of some
ketones and ethyl acetate by the cultures under scrutiny seem to reflect
ADHs and ALDHs expression and further confirm the detoxification role
of the adipocytes in human organism. If so, the adipose tissue could
play a more active role in metabolic regulation in general and detox-
ification mechanisms in particular, as is currently assumed. Isoprene
and sulphur compounds have also been reported to be increased in
diabetic patients' breath. The results of this study imply that, at least
partially, these VOCs originate from the adipose tissue. Although, the
origin of the observed furan-containing compounds remains unclear,
they might be related to some unique metabolic functions of the adi-
pose tissue and therefore have some diagnostic potential. As the fuel
reservoir, adipose tissue controls the lipid mobilization. Therefore, the
adipose tissue dysfunction can be reflected by changes in the human
volatilome, which could in turn be detected non-invasively via breath,
or urine analysis. The occurrence of species stemming from lipid per-
oxidation could, in this context, be considered as valuable markers of
this metabolic state.
Several limitations of the study should be raised. First, this study has
been conducted with a human adipocytes cell culture model, using cells
derived from a patients suffering from Simpson-Golabi-Behmel syn-
drome. Thus, our data may not necessarily reflect the in vivo situation
of adipocytes in healthy subjects. Next, only C3–C11 species were tar-
geted. Consequently, heavier volatile compounds may be produced but
are not reported in the present study.
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